A Phase I Trial Testing TH-302, a Tumor-selective Hypoxia-Activated Cytotoxic Prodrug, in Combination With Preoperative Chemoradiotherapy in Patients With Distal Esophageal and Esophago-gastric Junction Adenocarcinoma

Trial Profile

A Phase I Trial Testing TH-302, a Tumor-selective Hypoxia-Activated Cytotoxic Prodrug, in Combination With Preoperative Chemoradiotherapy in Patients With Distal Esophageal and Esophago-gastric Junction Adenocarcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Evofosfamide (Primary) ; Carboplatin; Paclitaxel
  • Indications Oesophageal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Aug 2016 Trial design published in the BMC Cancer.
    • 20 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 10 Nov 2015 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top